NANOSONICS LIMITED — AGM Information 2015

Nov 5, 2015

Nanosonics Limited 2015 Annual General Meeting

Friday 6 November 2015

Nanosonics Board, Secretaries and Auditor

Nanosonics Limited 2015 Annual General Meeting

Business of the meeting

Resolution 1 Election of a Director – Richard England

Resolution: That Richard England, who retires as a Director pursuant to the Company's Constitution and, being eligible, offers himself for re-election, be elected a Director.

Votes for	:	149,465,324
Against	:	2,374,563
Abstained/Excluded	:	404,728
Discretion	:	547,935

Resolution 2

Remuneration report

Resolution: That the Remuneration Report for the financial year ended 30 June 2015 be adopted.

Votes for	:	122,175,631
Against	:	3,948,462
Abstained/Excluded	:	27,150,341
Discretion	:	573,435

Resolution 3

Issue of Performance Rights to the CEO and President under 2015 LTIS

Resolution: That approval be given for all purposes under the Corporations Act 2001 (Cth) and the Listing Rules of ASX Limited:

a) for the issue of 206,882 Performance Rights to Mr Michael Kavanagh under the Nanosonics Employee Share Option Plan (ESOP) in respect of the 2015 LTIS; and

b) in consequence of the vesting of those Performance Rights, fully paid ordinary shares in the Company on the terms set out in the Explanatory Notes accompanying the Notice of Meeting and in accordance with the Rules of the Nanosonics ESOP (as amended from time-to-time).

Votes for	:	151,076,637
Against	:	836,748
Abstained/Excluded	:	329,883
Discretion	:	552,935

Resolution 4

Issue of Performance Rights to the President Technology Development / Commercialisation under 2015 LTIS

Resolution: That approval be given for all purposes under the Corporations Act 2001 (Cth) and the Listing Rules of ASX Limited:

a) for the issue of 70,992 Performance Rights to Dr Ronald Weinberger under the Nanosonics Employee Share Option Plan (ESOP) in respect of the 2015 LTIS; and

b) in consequence of the vesting of those Performance Rights, fully paid ordinary shares in the Company on the terms set out in the Explanatory Notes accompanying the Notice of Meeting and in accordance with the Rules of the Nanosonics ESOP (as amended from time-to-time).

Votes for	:	150,898,686
Against	:	796,863
Abstained/Excluded	:	500,646
Discretion	:	552,935

Nanosonics Limited 2015 Annual General Meeting

Chairman's Address Mr Maurie Stang

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation. Certain information may relate to protected intellectual property rights owned by Nanosonics (the "Company"). While Nanosonics has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

2015 – A year of significant achievement and transformation

North America grew to 5,000 in FY15, now > 5,700

Nanosonics' North American direct sales organisation now successfully implemented

Move to expanded new state of the art corporate, R&D and manufacturing

2015 – A year of significant achievement and transformation

Successful Placement and Share Purchase Plan raised \$28 million to support growth strategy

Comprehensive clinical studies program implemented supporting standard of care

R&D strategy focussing on Infection prevention. For life with powerful roadmap and pipeline in place

Strong global momentum for guidelines and regulation for prevention of Hospital Acquired Infections (HAIs)

May 2014 NEJM paper recommended increasing surveillance and prevention activities to fight HAIs

"Our nation is making progress in preventing healthcareassociated infections through three main mechanisms:

• financial incentives to improve quality;
• performance measures and public reporting to improve transparency; and
• and the spreading and scaling of effective interventions.

This progress represents thousands of lives saved, prevented patient harm, and the associated reduction in costs across our nation."(1)

1. Patrick Conway, MD, deputy administrator for innovation and quality for the Centers for Medicare & Medicaid Services (CMS), and CMS Chief Medical Officer

Governments and accrediting bodies responding to the challenge of HAIs

	CMS.gov	Centers for Medicare & Medicaid Services			Learn about your healthcare options:	Home About CMS Newsroom FAQs Archive Share Help Print
Modicare	Madicald/CHP	Medicare Medicaid Coordination	Private Insurance	francysticas Cantar	Requiations & Guidance	Research, Statistics, Data & Systems	Outreach & Education
	Hospital Value Baued Purchasing Program CONTRACTOR CONTRACTOR					Horse + Decoration + Media Referent Determine > Part Islands + 2014 Part Islands Dame + Plazal View 2015 Results for the CMS Hospital Acquired Condition Reduction Program and
Fact sheets Rattorn to Newsmans						Fiscal Year 2015 Results for the CMS Hospital-Acquired Condition Reduction Program and Hospital Value-Based Purchasing Program
		Date a ma		2014-12-18
		Title

The Hospital-Acquired Condition (HAC) Reduction Program in the US is the result of reforms under the Affordable Care Act¹

Non compliance with infection control standards associated with medical equipment & devices is one of the top 5 findings by The Joint Commission²

1. Electronically accessed: thejointcommission.org. May 2014. Issue Two. Improperly sterilized or high-level disinfected equipment.

Risk of cross contamination with reusable devices recently reinforced

CDC/FDA Alert September 2015

Reusable medical devices must be properly maintained, cleaned and disinfected/sterilized. Healthcare facilities urged to immediately review current reprocessing practices to protect patients.

• CRE "superbug" outbreak in the US linked to contaminated duodenoscopes in a number of healthcare facilities across the US
• Linked to at least 13 deaths
• FDA issued alert in March 2015 and now enforcing stricter guidelines
• Alert on contaminated bronchoscopes also issued in September 2015

FY15 revenue and cash balance

Pleasing sales revenue achieved as North American direct sales operations established

Strong cash reserves to support growth plans

Nanosonics included in ASX 300 in March 2015

	30 Jun 15	30 Jun 14	30 Jun 13
Total shares issued (million)	282.91	263.82	261.99
Share price	\$1.70	\$0.79	\$0.61
Market capitalisation (million)	\$481	\$208	\$159
Average daily volume (12 months)	531,000	349,000	198,000

Media coverage highlights

Comprehensive positive media coverage during the year

New state of the art global headquarters supports strategic growth objectives

Strong product development and R&D pipeline

Nanosonics well positioned to capitalise on the high growth global market for infection prevention.

• Approximately \$5 million invested in product development and R&D activities across mechanical, electrical and software engineering, microbiology and chemistry.
• Active engagement with global experts and societies in defining the next generation of product requirements.
• Powerful product roadmap supporting future growth opportunities in core product and rapidly expanding market in infection prevention.

Nanosonics Limited 2015 Annual General Meeting

CEO's Address Mr Michael Kavanagh

Executive Team

McGregor Grant CFO and Company

Gerard Putt Head of Manufacturing & Operations

Michael Potas Head of RD&D

Vincent Wang Head of Global Services

Ruth Cremin Head of Quality and Regulatory

Kirste Courtney Human Resources

Andrew Murray Head of Global Marketing

Ron Bacskai President and CEO Nanosonics Inc.

Ralf Schmähling Country Manager - Germany

Julien Laronze Country Manager - France

Nanosonics' mission

We improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted, and introducing innovative technologies that deliver improved standards of care.

Corporate objectives

Customer Experience

Establish our offerings as new standards of care globally and provide customers a convenient, seamless and consistent experience with both product and brand.

Product Innovation

Create and bring to market a portfolio of innovative and quality products that address unmet customer needs providing higher standards of safety, efficiency and patient care.

Operational Excellence

Develop an agile operation with scalable, compliant and performance focussed processes, designed to deliver a positive experience for our customers.

People Engagement

Build an organisation that attracts and retains the best people and engages and empowers them to take appropriate initiative and be accountable for our core objectives.

Value Creation

Create sustainable shareholder value, delivering high growth and strong returns , while making a significant contribution to social good.

Customer Experience – FY15 highlights

Commenced Direct Operations in North America

Expanded European Presence into 5 new countries

Grown installed base to > 5000 in US (at June 30) including adoption in many luminary sites

Implemented extensive clinical outcomes program

Supported development and adoption of new guidelines

Implemented a range of new sales tools and customer training initiatives

Implemented Service operations in US and Europe

Commenced partnerships with key associations e.g. APIC

. Establish our offerings as new standards of care globally and provide customers a convenient, seamless and consistent experience with both product and brand

Customer Experience

25

Product Innovation – FY15 highlights

Active R&D Subcommittee of Board
Engaged with key infection prevention societies and opinion leaders
Defined Product Roadmap
Progressed our research across trophon, new chemistries and new IP solutions
CONFIDENTIAL 

Create and bring to market a portfolio of innovative and quality products that address unmet customer needs providing higher standards of safety, efficiency and patient care.

Operational Excellence – FY15 highlights

Moved HQ, R&D center and manufacturing operations to state of the art facility
Set up new premises in UK and Germany
Updated our IT Infrastructure
Expanded ERP system to support global operations
Set up infrastructure to support US operations
Continued implementing LEAN principles across the business

Develop an agile operation with scalable, compliant and performance focussed processes, designed to deliver a positive experience for our customers.

People Engagement – FY15 highlights

Engaged and aligned the organisation through mission and clarity around Corp. Objectives

Attracting top quality people to company across all disciplines

Formalised Human Capital Planning across the business

People Engagement

Build an organisation that attracts and retains the best people and engages and empowers them to take appropriate initiative and be accountable for our core objectives.

Value Creation – FY15 highlights

Create sustainable shareholder value, delivering high growth and strong returns, while making a significant contribution to social good.

FY2015 revenue and cash balance

Pleasing sales revenue achieved as North American direct sales operations established Strong cash reserves to support growth plans

FY16 Q1 Sales of \$6.46 million with cash balance of \$45.5 million

Regional Review

North American direct sales operation successfully implemented

• Direct sales operation covering all US territories established
• 18 highly qualified sales professionals trained and focussed on building sales pipeline
• Warehousing, order fulfilment and direct service fully operational
• Establishing Nanosonics as leading infection prevention brand to support trophon & introduction of future infection prevention solutions

North American adoption continues to grow strongly

• Installed base of 5,000 units at end of FY15 now grown to 5,700 as at end Q1 FY16
• Market opportunity of 40,000 units
• Trophon now represented in 43 of the top 50 hospitals

Direct sales focussed across all ultrasound brands trophon now compatible with more than 900 ultrasound transducer models

• Expanded number of ultrasound probes approved with trophon from 600 to 900
• Covers all world's leading manufacturers
• Includes both intracavitary and surface probes

Europe/ROW sales growing strongly

• FY15 sales of \$2.3 million up 45% on pcp
• UK primary driver of sales in the period with FY15 installed base ~250 units across 40 sites
• New Welsh guidelines supporting trophon and guidelines in England and Scotland in development
• European distribution expanded into five new countries (Austria, Belgium, Italy, Luxembourg and the Netherlands) with distribution partner, Miele Professional

Potential impact of guidelines

New NHS Wales Guidelines position automated, validated decontamination systems as the optimal solution for ultrasound probe decontamination

Wales

All Health Boards in Wales have now commenced with trophon following the introduction of guidance in 2014

Installed base pre guidance 0 Installed base post guidance 76

Approx 50% market penetration in 12 months across TV / TR departments

Scottish and English guidelines pending

HFS Survey shows everybody is using manual reprocessing methods and most with no traceability

Number of trophon units installed in Glasgow and Aberdeen in advance of guidelines

English guidelines currently under review and expect publication in "Journal of Hospital Infection" TBD

Already installations across 7 hospital settings including largest NHS trust in London

Growing interest in Ireland

HIQA - Health Information and Quality Authority driving for improved practices for Ultrasound Probe Decontamination to replace CIDEX OPA

Active program of education and support across UK

• National Infection Prevention Society conference
• Regional Infection Prevention Society Meetings
• Institute of Decontamination Sciences
• British Medical Ultrasound Society
• Central Sterilising Club
• British Society of Gynaecological Imaging
• Health Facilities Scotland Decontamination Conference

European expansion with Miele

Netherlands

Education day for all ultrasound manufacturers in Germany

09:30 Uhr	Begrüßungskaffee
10:00 Uhr	Begrüßung Martin Hübner, Miele Professional
10:05 Uhr	Grundsätzliche Rechtsfragen zur Aufbereitung von Ultraschalls Hans-Werner Röhlig, Amtsgericht Gladbeck
11:00 Uhr	Viruswirksamkeit der Instrumentenaufbereitung unter besonde Berücksichtigung von Ultraschallsonden Dr. Jochen Steinmann, Dr. Brill + Partner GmbH
12:00 Uhr	Mittagspause
13:00 Uhr	Verfahren zur Aufbereitung von (semi-)kritischen Ultraschallso Dr. Sebastian Werner, Ruhr-Universität Bochum
14:00 Uhr	Desinfektion von transvaginalen Ultraschallsonden im klinische Dr. Kerstin Hammer, Klinik für Frauenheilkunde, UK Münster
14:30 Uhr	Aufbereitung von Ultraschallsonden aus Sicht des niedergelas Doris Scharrel, Landesvorsitz Schleswig-Holstein, Beisitzerin i Berufsverhand der Frauenärzte e.V.
15:00 Uhr	trophon EPR - Marktstrategie und Synergieeffekte Günter Heller, Miele Professional / Raif Schmähling, Nanosoni
	15:30 Uhr Schlussdiskussion
	a contract in the state of the state contract of the state

Broad market awareness and education activities

M&K April 2015 HygMed 2015

ANZ setting the benchmark for standard of care

Standard of Care – Clinical studies

HPV risk

• Human Papilloma Virus (HPV) is associated with 99.7% of cervical cancers as well as a number of other cancers including anal, vaginal, vulvar and penile¹
• HPV Types 16 and 18 account for 5% of all cancers worldwide²

• 1. Walboomers JMM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12–19.
• 1. Parkin DM (2006). "The global health burden of infection-associated cancers in the year 2002". Int. J. Cancer 118 (12): 3030–44.

HPV – A real risk of cross contamination through ultrasound examination

COSA-CE ACTESS though available com-		$\mathcal{D}$ PLOS $\rightarrow$
Nosocomial Infection?		High Risk HPV Contamination of Endocavity Vaginal Ultrasound Probes: An Underestimated Route of
Patrice Mathewet", Yahia Mekki 1 *		Jean-sebastien Cassiegne 1+ , Karine Le Ball Carval 9 , Daniel Elbach 1-9 , Marie Laure Valdeynsn 9 , Gery Lamblin 3 , Hervé Jacquemoud 9 , Georges Mellier 3 , Bruno Lina 2 , Pascal Gaucherand 2 ,
Francis Mismaxian Public Insults Mandanisms Frankry A.		1 Lebandar of History, Samuel Middle & Middlega St. Howard Collision Law, Samuel Stylesman (Newmark), Newmark Collision Law, Law These Microsoft Samuel Middless Institute Microsoft Radioa Controls News Howards and Collisi
es Moubel Civil de Luis		Transvaginal ultrasound probe contamination by the
Abstract		human papillomavirus in the emergency department
Rackpround Entire print Thismean' without connect visit Human Papilloniants indocevity ultrassured in conserving wipes.		Shuk Ting Christine Ma. 1 A C Yeung. 2 Paul Key Sheung Dhan. 2 Colin A Graham 1
punt community) just hattow the profes in 197V genotypes! Results We collected 211 King Hing King Lesso, Human DFA was I wittssound LLD proceeds	Methods: from May 14 Vocare ad bragany Department of the Liga Metors Nusters Inc. To Clemat Unserstand Herg. Kang Herg Keep Tagement of Montes Teach of Modern, The enwr it Medalup: Direct (theorists of Yong )	ABSTRACT Objective To determine if human picklements OPM supply the months forced on follows: classes, OW can be deterred on the homospher conceptative (IV) ande in the emergency department IED, and whether the current banks minute plus distribution com- pieert HPV stritutionism of the TVS prebx. Methods This was a two-part simulatedrond study. At the first part, nunvellates surrally were taken from the TVS probe for HPV IZINF detection daily for 2 months. In	gracy Aspetrsons (815). The new of ultraverag- measurable programs and althousial authorities and pericastial nemporado os toxima patients 2 Many studes have demonstrated that energotay phylicats perheraal alloassequedy can be very suchal in the management of antic programs; Meeting 2-12 work potential inductions or the
Conclusion: Our study or	times Hammel CO procedure Communication to pre-examination camples to then for themselves the pre-examination camples to their formation of the process of Conclusions that study on Memme is assumed that the Through University of Hora
CHA, steaght 11/2 short		and son necessary	U PLOSI-
CHUR, shoulde 312 about King 17. Max little floor at a state of the state of the state and the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of t Hard King Chiefman Countigue (+1 in Park 2) (Philosophilan (Tagradi com Mike Ai Hubert, PO WEIG RIGHT I JUN 2012 Rendered August 3, 2010, Bouge Engineer & And Company Forefing this may has been feel d'Ora, de siting d'As nones Pe Serviki: volets Enriquiting Interests: The suits 1 E-true la principalmente constituzioni Introduction Hyron parlimentos (H) sinkapital come of invasive is thelial synchus and hole is growspy, chadred into high UP6 2-4-RPV 6, 11:20, art (6) The bigh rids generate previously with company can intractibility reception. We Wh of contrad resents are a Grand HPV interime is made FLOR SAN www.pliceme.com	Persistence of Microbial Contamination on Transvaginal Ultrasound Probes despite Low-Level Disinfection Procedure follow SF2A 17 , three density", banking using "Allia model" (family density family). Mohael Apro box town in bookman, determiner dealer health and determined about health health and developed the book Billian An all the think in this control to the state that the base of state movement directly areas. antly replace conditions of its sloga art conclusigations. panyak pada Manisasi (propins controllero control politica) panyak propinsi transformating control. Mit gan de del las el questo del 1 se formal del escriptores por destacar la bandidad en Estatunidad conden- Las constantes en Estatunidad contentante al confiderat la sua la sua la della contentación de del c and long-rank demolisated as concerning control.	and the characteristic control of the control Alexandria (Alexandria) and a contemporary state of the computer state between the fundamental process and the property of the computer to sale that the company interest and management that a partial information expected interesting water. Interference property for an other to the of the project accordable to their place and a price must of do of the product for the children's division General Art Today, and research plant CA. (Thirty of Hammark) them it is not man in Mathematic di- Sharehouse through the Sharehouse and collection of Hammark and Care and Hammark and Care and If the attention them alone dony descriptions of exhaust to bell to move to
	"Copyright Article aid	Basic Authority, Michigan Antonio ment in the Art & Collegeant States in Art Edmonton Martin 2014 MA CASTER 12 Drug Entrance and changes the Auto of a Designation and the tradematic Countries and announcement. Bellevaled Monetabally in speech and human log-	enting is little entered in fractionical Data ADM-Ards the permit democratisate is to other Blacked child with
		at log-sin-on at a capacitie of oppositely as containing that registria aplica il del configurazione finanzani the shocker puts a cabled packaged by PLAT & @ Policy Start ALCANY evaluation on a during their subsets to play copied on feath. To make you falls St All He advertising absentationalism at characteristic a high-siz- leaks also reduce the probe select and continue must water from the plate construction and the recorded in column system in these work	Delivery well to in society is an installation that relationship to the U.S. in Contract for an in a in decay home is finance a first a of Contact Man West Profit Land is the programming of a process with and then the department the de- Minimize all week dealerships and a positive discussion of the tracked dealed durant in the amount of collects are produces out above it is pure out minor more looks with drive 4-to-levels & poste & are offering particle exhibitions with the security

• "a considerable number of ultrasound probes contaminated with human and HR-HPV DNA, despite LLD disinfection and probe cover" ¹
• A substantial persistence of microorganisms observed on disinfected probes: HPV DNA found on 13% of samples"²

• "HPVs are very stable viruses, able to survive on fomites and surfaces for days" ³

• 1. Casalegno et. Al.: High Risk HPV Contamination of Endocavity Vaginal Ultrasound Probes: An Underestimated Route of Nosocomial Infection?, PLOS ONE, Oct 2012, Volume 7, Issue 10
• 1. M'Zali et al. Persistence of microbial contamination on transvaginal ultrasound probes despite low-level disinfection procedure. PLoS One 2014;9:e93368.
• 1. Ryndock EJ, Meyers C., A risk for non-sexual transmission of human papilloma virus? Expert Rev. Anti Infect. Ther. 12(10), 1165-1170 (2014).

Disinfectants commonly used on ultrasound probes do not kill HPV

Glutaraldehyde and OPA shown to be totally ineffective against natural, infectious HPV, even with longer contact times

Meyers, J., et al., Susceptibility of high-risk human papillomavirus type 16 to clinical disinfectants. J Antimicrob Chemother, 2014

Currently only one system proven to kill HPV - trophon

GUIMMARY - We previously deposit WV was lighty twisted for photosterium silitorium artiso arhanische a 1996 in a 60 tion dealer comments that	METHODS: 1. Virus Production	RESULTS The prophase VI/III is virtualidat against Justin HPV16 and HPV18.
/ The ordinance is show high trust dominisms (N/I), are seniory used to responsive under ordered farms excluding probably all solared probat-		control experience of them. The C. C. Station
1. Als had man larked SRs. Against the and at a demoted della A accesiona gliè resonnessini un gournier- Thiese 31. Lember asuto water perfections to characterize requirements for innuited modifier	Seed your on carrier
- The amendment addentical bay, naturize and Length collection hashingto (Fig. Ad includes ingelection and SR c.rk columns in Lip., Indeeding INTRODUCTION	Students
1. Kompozations plus 2010 is a participated agent of sendal, anagerite and registrategist cause.	Disinfact Test Carrier
- While and others are associated with the reservice of ARV Industrial Asia II.
1. Maximum WH comes have leased an interacular affiction of presented by the property of the control of the	Council Charles Council Business Commercial Commercial STAR or humanitaries Jessense 2 (246)	CONCLUSION
> Garlert direct represents instead color (15 and 205) loans Allis are not sharing lasers want 10 mins MH				Teacher
Share for	4. Neutralis Published FLIGAAK 5. Infactivity	Akademia	Œ
	Home Li		Band for an
	Listing 2011/11/1 at it to take the Bus sweeted 1 Director Agent Co.		Poli McLiusec
		Businghtbilds of HPV10 and 18 to high level distributoris matured for sent-infilial altrasound probes.	Address College
	Rowano & " Gameso AT Jonate J." 2 Administration		Start Agency
			12. Aug as Freedom . 4
		NACK SERVICES 1 Reserved protect and in entity or halv, yets below that is been to be comparisoned with high data PBV play science, and lett- (45) to also hanner to be resident to write high fand deemerkers. (402a). This state companies who are at his familia distribution and a fifth
	and 10717 to a backstallack carler well. ÷	contrast. Next officialitations closed CPAs and as a procedure to a constant turn and considerable procedure (PR) against (PVA).	Stories adopted Contrator of an approvise top lanet
	Testimony of the condition with the dealer of the con-	METHODS halo a 197/10 will WP2 to seas your president in regardajor self-adapted colours. Vital to date rate sites only on a retail of the TB. (LY) ploten call ATALer's tame was carriered against the substituted air or at \$150, and \$1.000, PC (2) pro \$1.070, OPA in qualitate attracts of	Books for bested to triply from Texas. 2015 There per letter and high-ring dealers constituting about
	mW1410R of the approxi 211Rd to execute to infer because it with	mainstream is announced to any consent control than Hole and related as a profit or priori transition as alternately the above are	tax Markham Manuel Service 201
		RESALTS: The automated Http service interest advance of lease appeal HPV/II, and MPV/II, in Equal passengers in minority of interest and the UPA	A restructional striple-Medi-Limpanion of the- Merivannes of Think Fuse city (19) 14 .323
	drivened askrategic prificance in 12.5 from a restaurant of	CONTLEMATES 1994 (IF) to high, receiver to OTA, mon deal to drope (avoids) after an offertive desires too under to ideas and power	Phoney contentiated areas: while his of Termins V. stationism and Color entire at (1 Toricock, 1927)
	They deliver to conventible to a state task, we may be a state that	Charleries tradicies that are offereity appear HPV struckles associate cruises grandity. This precisio is arounded by copyright. All rates seasonal.	Vince that with sales of the images parameter relations UserApylost 22 9 to 1 4 to 1 2011
		SETWARE TO AN EXTREME PEEL PROPERTY AND PRESSURE TO AN INC.		The A de America Tel: 41
	NASA LINESIMA Primaria - La hamistic for soldio etc.
			Based Antivity
	数々語
	LAYATIVE - DECAL/ASTRONOMIA		SALE IN 市 Thomas Kalin at MPV 15, and 10 to truck taxed 2010/01/01 14:04:05 (400) 1 - 71:00
	Publicat Corporates	Canada German House	Executive of transvigeral observers m andwe is a chiest welling companiti-

• Second Meyers study retested OPA and also investigated ability of trophon, an automated high level disinfection system for ultrasound probes, to kill HPV
• Results confirmed OPA to be ineffective but showed that trophon EPR totally kills natural, infectious high-risk, cancer-causing strains of HPV
• Results presented at SHEA and APIC 2015
• Accepted for publication in peer review Journal of Medical Virology

Ryndock E, Robison R, Meyers C. Susceptibility of HPV16 and 18 to high level disinfectants indicated for semi-critical ultrasound probes. J Medical Virology 2015. In press. 47

Strong product development and R&D pipeline

Nanosonics well positioned to capitalise on the high growth global market for infection prevention.

• Approximately \$5 million invested in product development and R&D activities across mechanical, electrical and software engineering, microbiology and chemistry.
• Active engagement with global experts and societies in defining the next generation of product requirements.
• Powerful product roadmap driving future growth opportunities in core product and rapidly expanding market in infection prevention.

Business outlook

• FY16 first quarter results encouraging during North American direct operations transition period.
• Focus on building direct sales pipeline
• Market fundamentals continue to strengthen
• Increased attention by regulatory authorities
• Supporting guidelines for automated HLD solutions
• Excellent clinical data demonstrating superiority of trophon
• Continuing to expand regional operations
• North America direct operations
• European expansion
• Expansion into Asia Pacific
• Strong product development and R&D pipeline